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Brain neurotransmitter transporter/receptor genomics
and efavirenz central nervous system adverse events
David W. Haasa,b, Yuki Bradfordc, Anurag Vermac,d, Shefali S. Vermac,
Joseph J. Eronh, Roy M. Gulickf, Sharon A. Riddlere, Paul E. Saxi, Eric S. Daarj,
Gene D. Morseg, Edward P. Acostak and Marylyn D. Ritchiec,d
Objective We characterized associations between central
nervous system (CNS) adverse events and brain
neurotransmitter transporter/receptor genomics among
participants randomized to efavirenz-containing regimens
in AIDS Clinical Trials Group studies in the USA.
Participants and methods Four clinical trials randomly
assigned treatment-naive participants to efavirenz-
containing regimens. Genome-wide genotype and
PrediXcan were used to infer gene expression levels in
tissues including 10 brain regions. Multivariable regression
models stratified by race/ethnicity were adjusted for
CYP2B6/CYP2A6 genotypes that predict plasma efavirenz
exposure, age, and sex. Combined analyses also adjusted
for genetic ancestry.
Results Analyses included 167 cases with grade 2 or
greater efavirenz-consistent CNS adverse events within
48 weeks of study entry, and 653 efavirenz-tolerant
controls. CYP2B6/CYP2A6 genotype level was
independently associated with CNS adverse events (odds
ratio: 1.07; P= 0.044). Predicted expression of six genes
postulated to mediate efavirenz CNS side effects
(SLC6A2, SLC6A3, PGR, HTR2A, HTR2B, HTR6) were not
associated with CNS adverse events after correcting for
multiple testing, the lowest P value being for PGR in
hippocampus (P= 0.012), nor were polymorphisms in
these genes or AR and HTR2C, the lowest P value being
for rs12393326 in HTR2C (P= 6.7× 10− 4). As a positive
control, baseline plasma bilirubin concentration was
associated with predicted liver UGT1A1 expression level
(P= 1.9× 10− 27).
Conclusion Efavirenz-related CNS adverse events were
not associated with predicted neurotransmitter transporter/
receptor gene expression levels in brain or with
polymorphisms in these genes. Variable susceptibility to
efavirenz-related CNS adverse events may not be explained
by brain neurotransmitter transporter/receptor
genomics. Pharmacogenetics and Genomics 28:179–187
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Introduction
Efavirenz is a frequently prescribed antiretroviral, with
its efficacy demonstrated in multiple clinical trials [1–6].
However, central nervous system (CNS) symptoms
are common with efavirenz [7–9]. Several CYP2B6 poly-
morphisms predict increased plasma efavirenz exposure,
including CYP2B6 516G→T (rs3745274) [10–15], 983T→C
(rs28399499) [15–18], and 15582C→T (rs4803419) [15].
A CYP2A6 polymorphism, − 48T→G (rs28399433), also
affects efavirenz pharmacokinetics [19–22] when
present with CYP2B6 slow metabolizer genotypes
[19,22]. These polymorphisms explain ~ 35% of inter-
individual variability in plasma efavirenz exposure [15].
A possible association with efavirenz pharmacokinetics has
also been reported with UGT2B7 genotype [21], but with
small effect size [22].
Increased likelihood of efavirenz CNS symptoms has
been attributed to CYP2B6 slow metabolizer genotypes
[18,23,24]. In an initial analysis of AIDS Clinical Trials
Group (ACTG) data [18], CYP2B6 slow metabolizer
genotypes were associated with adverse events in 276
White participants (P= 0.04), but not in 217 Black par-
ticipants (P= 0.58). Similarly, among 563 patients who
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boards approved each study, and participants provided writ-
ten informed consent.
Outcomes
The outcome of interest was new onset grade 2 or greater
CNS signs or symptoms that were consistent with possible
efavirenz effect. These included agitation, behavior changes,
abnormal cognition, confusion, depression, difficulty con-
centrating, dizziness, abnormal dreams, excessive anger,
hyperactivity, inappropriate behavior, insomnia, lethargy,
change in level of consciousness, light-headedness, memory
loss, psychiatric mental status change, rage, or sleeping pro-
blems. Adverse event data were based on self-report, and did
not involve questionnaires specifically targeting CNS events.
Death by suicide was also considered a possible efavirenz
effect.
Cases were participants with grade 2 or greater efavirenz-
consistent CNS signs or symptoms, or with death due to
suicide, documented within 48 weeks after study entry
while still being prescribed efavirenz, or within 2 weeks
after efavirenz was discontinued. Controls were participants
with no documented efavirenz-consistent CNS signs or
symptoms regardless of any grade after study entry while
being prescribed efavirenz for at least 96 weeks. Cases and
controls were excluded for any neuropsychological signs or
symptoms of any grade documented at study entry.
Covariates
Baseline covariates included in multivariable models included
age, sex, and CYP2B6/CYP2A6 genotype. The first two
principal components generated from genome-wide geno-
type data were also included to minimize confounding by
unrecognized population stratification. Analyses performed
separately among self-identified White, Black, and Hispanic
participants also adjusted for age, sex, and CYP2B6/CYP2A6
genotype, but not principal components.
Genetic assays and data
Genotypes for CYP2B6 516G→T, 983T→C, 15582C→T,
and CYP2A6 − 48T→G were largely available from a
MassARRAY iPLEX Gold (Sequenom Inc., San Diego,
California, USA) assay, generated by Vanderbilt Technologies
for Advanced Genomics [15]. Genome-wide genotype data
largely available from a previous immunogenomics project
[31] were generated by Illumina HumanHap 650Y array for
A5095 and by Illumina 1M duo array for A5142 and A5202
(Illumina, San Diego, California, USA). Quality control and
imputation of genome-wide data were performed as described
elsewhere [32]. The PLINK program and R statistical pro-
gramming language were used for QC procedures [33,34].
Polymorphisms were censored for call rates of less than 99%.
We excluded 18 samples where genetically inferred sex dif-
fered from clinical data, or missing sex status that could not be
inferred, 105 samples with overall genotyping call rates less
than 99%, and 17 samples with cryptic relatedness based on
initiated efavirenz-containing regimens at a clinic in the 
Southeastern USA, slow metabolizer CYP2B6 genotypes 
were associated with efavirenz discontinuation for CNS 
symptoms in 335 White patients (P = 0.001), but not in 
198 Black patients (P = 0.27) [23]. Among 1833 ACTG 
study participants in the USA, an association between 
CYP2B6 genotype and suicidality was strongest among 
White participants, but nearly null among Black partici-
pants [24]. The reason for this apparent difference by 
race is not known.
Brain neurotransmitter transporters/receptors are postu-
lated to mediate efavirenz CNS symptoms, including the 
norepinephrine transporter (encoded by SLC6A2), dopamine 
transporter (SLC6A3), progesterone PR-B (PGR), serotonin 
receptors 5-HT2A (HTR2A), 5-HT2B (HTR2B), 5-HT2C 
(HTR2C ), and 5-HT6 (HTR6), and androgen receptor (AR)
(Daria Hazuda, personal communication, 1st March 2016). 
Lower expression levels of neurotransmitter transporter/
receptor genes in brain tissue could possibly confer increased 
susceptibility to efavirenz side effects. This hypothesis may 
be addressed indirectly using, PrediXcan, a novel computa-
tional algorithm that uses genome-wide genotype data to 
infer RNA expression levels for individual genes in various 
human organs and tissues [25].
We examined whether predicted expression levels of 
selected neurotransmitter transporter/receptor genes in 
brain were associated with risk for CNS adverse events in 
participants randomized to receive efavirenz-containing 
regimens in ACTG studies. We also examined whether 
individual polymorphisms in these genes were associated 
with CNS adverse events with efavirenz.
Participants and methods
Study design and participants
Data were pooled from antiretroviral-naive individuals 
who had been randomly assigned to initiate efavirenz-
containing regimens in four studies: ACTG384 (ClinicalTrials. 
gov: NCT00000919) [26,27], A5095 (ClinicalTrials.gov: 
NCT00013520) [2,28], A5142 (NCT00050895) [3], and 
A5202 (NCT00118898) [6]. Drug class components of the 
regimens were randomly assigned (efavirenz-based regimen 
vs. comparator regimen) except for nucleoside analog choice 
in A5142. Genetic association testing was limited to parti-
cipants who consented to genetic testing under ACTG 
protocol A5128 [29]. Participants self-reported race/ethnicity.
Each protocol required reporting of signs, symptoms, or 
diagnoses at each visit, severe and life-threatening graded 
signs or symptoms [30], and signs or symptoms that led to 
change in study regimen. Diagnoses were not graded. 
Further, study A5142 required report of all moderate signs or 
symptoms, study ACTG384 required entry of all signs and 
symptoms grade 3 or greater, all signs and symptoms that 
resulted in dose modification regardless of grade, and all grade 
2 or greater CNS symptoms, and A5095 and A5202 required 
report of moderate CNS symptoms. Site institutional review
identity by descent estimates more than 0.3 from ~100 000
pruned single nucleotide polymorphisms (SNPs).
Post-QC data were imputed to 1000 Genomes [35] after
converting to genome build 37 using liftOver [36] and stra-
tifying by chromosome to parallelize imputation processing.
ShapeIt2 [37] was used to check strand alignment and to
phase data. The IMPUTE2 algorithm [38] was used to
impute additional genotypes that were available in the 1000
Genomes reference panel, but not directly genotyped. Each
chromosome was segmented into 6Mb regions with at least
3500 reference variants in each region. Imputed genotypes
were included if posterior probabilities exceeded 0.9.
Quality of imputed data was assessed following the
Electronic Medical Records and Genomics protocol [39].
Each chromosome from each phase was checked for 100%
concordance with genotyped data. We dropped imputed
SNPs with info scores of less than 0.7, genotyping call rates of
less than 99% and minor allele frequencies of less than 0.01.
Twelve composite CYP2B6/CYP2A6 genotype levels that
predict progressively greater plasma efavirenz exposure were
defined by combinations of three CYP2B6 and one CYP2A6
polymorphisms [15,22] as described elsewhere [22]. Each
CYP2B6/CYP2A6 polymorphism (rs3745274, rs28399499,
rs4803419, and rs28399433) was in Hardy–Weinberg equili-
brium in White, Black, and Hispanic participants analyzed
separately except rs4803419 in White participants (multiple
testing-corrected P=0.045). Consent for genetic analysis was
obtained under ACTG protocol A5128 [29], and the ACTG
approved this use of DNA.
PrediXcan
PrediXcan was used to infer, from genome-wide genotype
data, the heritable component of RNA expression levels in
43 available reference tissues [25], using the 2015
PrediXcan models. PrediXcan was able to infer expression
of ~ 10 000 genes in each tissue. The 10 reference brain
tissues analyzed included anterior cingulate cortex, cau-
date, cerebellar hemisphere, cerebellum, cortex, frontal
cortex, hippocampus, hypothalamus, nucleus accumbens,
and putamen. The additional 33 reference tissues inclu-
ded adipose subcutaneous, adrenal gland, aorta, coronary
artery, tibial artery, breast, Epstein–Barr virus-transformed
lymphocytes, transformed fibroblasts, sigmoid colon, trans-
verse colon, gastroesophageal junction, esophagus mucosa,
esophagus muscularis, heart atrial appendage, heart left
ventricle, liver, lung, skeletal muscle, tibial nerve, ovary,
pancreas, pituitary gland, skin suprapubic not sun exposed,
skin lower leg sun exposed, terminal ileum, terminal ileum
(elastic net), spleen, stomach, testis, thyroid, whole blood
unscaled, whole blood, and cross tissue.
Statistical analysis
We characterized associations between predicted expression
of six autosomal brain neurotransmitter transporter/receptor
genes (SLC6A2, SLC6A3, PGR, HTR2A, HTR2B, HTR6)
and efavirenz CNS adverse events. We also characterized
associations between polymorphisms in these six genes as
well as AR and HTR2C and efavirenz CNS adverse events.
Because AR and HTR2C are on the X chromosome,
PrediXcan cannot infer their expression. Analyses controlled
for CYP2B6/CYP2A6 genotype level as a linear covariate, age,
and sex. The first two principal components, calculated using
EIGENSOFT [40] were used to adjust for global ancestry in
analyses that pooled all race/ethnicity groups. Associations
with CNS adverse events were evaluated using logistic
regression models, stratified by race/ethnicity. As a positive
control, associations between baseline total plasma bilirubin
concentration and hepatic UGT1A1 expression were similarly
evaluated, controlling for CYP2B6/CYP2A6 genotype level,
age, sex, and the first two principal components. The
Bonferroni method was used to adjust for multiple testing.
Results
Study participants
Of 4742 participants from ACTG studies ACTG384,
A5095, A5142, and A5202, a total of 2171 who had been
randomly assigned to initiate efavirenz-containing regimens
consented to genetic testing at research sites in the USA.
Of these participants, 1425 were successfully genotyped for
CYP2B6/CYP2A6 and had imputed genome-wide genotype
and principal component data. Of these participants, 820 met
definitions as either cases with documented grade 2 or greater
efavirenz-consistent CNS adverse events by week 48
(n=167) or efavirenz-tolerant controls that continued efavir-
enz for at least 96 weeks without documented CNS adverse
events (n=653). Participant disposition is shown in Fig. 1.
Baseline characteristics of study participants are presented in
Table 1. Females were underrepresented among cases versus
controls.
CYP2B6/CYP2A6 genotype and CNS adverse events
In logistical regression analyses, among the 820 participants
who were evaluable as either cases who developed grade 2 or
greater CNS adverse events by week 48 (n=167), or
efavirenz-tolerant controls (n=653), and controlling for age,
sex, and the first two principal components, CYP2B6/CYP2A6
genotype level was associated with grade 2 or greater CNS
adverse events within 48 weeks [odds ratio (OR): 1.07; 95%
confidence interval (CI): 1.00–1.15; P=0.044]. In analyses
performed separately among 335 White, 264 Black, and 184
Hispanic participants, and adjusted for age and sex but not
principal components, ORs for association between CYP2B6/
CYP2A6 genotype level and grade 2 or greater CNS event by
week 48 were similar to the total group (1.10 for White, 1.07
for Black, and 1.08 for Hispanic participants), but none were
statically significant (P>0.10 for each). In the above multi-
variable models, female sex was associated with fewer grade 2
or greater CNS adverse events within 48 weeks among all
participants (OR: 0.33; 95% CI: 0.17–0.63; P=0.001), and
among White participants (OR: 0.14; 95% CI: 0.18–1.04;
P=0.055) and Black participants (OR: 0.43; 95% CI:
0.19–0.96; P=0.040) analyzed separately.
Predicted expression levels of neurotransmitter
transporter/receptor genes and CNS adverse events
For each participant, genome-wide genotype data were used
to predict the heritable component of gene expression for 43
tissues, including multiple reference regions of the brain.
Primary analyses characterized associations between six
neurotransmitter transporter/receptor genes postulated to
mediate efavirenz effects in brain (SLC6A2, SLC6A3, PGR,
HTR2A, HTR2B, HTR6), and grade 2 or greater CNS
adverse events within 48 weeks. Among all participants, and
controlling for CYP2B6/CYP2A6 genotype level, age, sex, and
two principal components, the lowest nominal P value was
for PGR in hippocampus (P=0.012). The two lowest nom-
inal P-value results for each gene and associated brain regions
are presented in Table 2. None were significant after cor-
recting for multiple testing. In analyses performed separately
amongWhite, Black, and Hispanic participants, and adjusted
for age and sex but not principal components, there were no
significant associations. The lowest P value in White parti-
cipants was for HTR2A in cerebellar hemisphere (P=0.12),
in Black participants was for SLC6A2 in caudate (P=0.17),
and in Hispanics participants was for HTR2A in cortex
(P=0.082). The two lowest nominal P-value results for each
gene within race/ethnicity group and associated brain regions
are presented in Supplementary Table 1 (Supplemental
digital content 1, http://links.lww.com/NMC/A133).
Following the approach of Li et al. [41], we were able to
assess correlations between predicted and observed gene
expressions in reference datasets in brain tissue for
SLC6A3, HTR2B, and HTR6. Among Whites, the strongest
correlations were with SLC6A3 (r2=0.038) and HTR2B in
hypothalamus (r2=0.028). Among Africans, the strongest
correlations were with SLC6A3 in hypothalamus (r2=0.040)
Fig. 1
Derivation of the study sample. Derivation cases who developed grade 2
or greater efavirenz-consistent central nervous system (CNS) adverse
events by week 48, and efavirenz-tolerant controls who continued
efavirenz for at least 96 weeks without efavirenz-consistent CNS
adverse events, during participation in ACTG384, A5095, A5142,
or A5202 are shown. PC, principal components.
Table 1 Baseline characteristics of participants included in
analyses of grade 2 or greater central nervous system adverse








Parent study [n (%)]
ACTG384 28 (13.9) 173 (86.1) 201
A5095 63 (34.4) 120 (65.6) 183
A5142 15 (10.1) 133 (89.9) 148
A5202 61 (21.2) 227 (78.8) 288
Sex [n (%)]
Male 156 (16.4) 539 (77.6) 695
Female 11 (8.8) 114 (91.2) 125
Race or ethnic group [n (%)]
White non-Hispanic 81 (22.8) 274 (77.2) 355
Black non-Hispanic 53 (20.1) 211 (79.9) 264
Hispanic 26 (14.1) 158 (85.9) 184
Asian 2 (25.0) 6 (75.0) 8
Native American 3 (42.9) 4 (57.1) 7
Multiracial 1 (100) 0 (0) 1
Unknown 1 (100) 0 (0) 1
Age [median (IQR)]
(years)
38 (31–45) 37 (31–45) 37 (31–45)
IQR, interquartile range.
Table 2 Associations between predicted expression levels of six
autosomal neurotransmitter receptor/transporter genes and grade
2 or greater central nervous system adverse events within
48 weeks of starting efavirenz-containing regimens
Genes Chromosome Brain region β P value
HTR2A 13 Cerebellar hemisphere −0.61 0.086
Frontal cortex −1.24 0.677
HTR2B 2 Frontal cortex −0.77 0.331
Hippocampus −0.31 0.601
HTR6 1 Nucleus accumbens 0.45 0.258
Caudate 0.53 0.587
PGR 11 Hippocampus −0.91 0.012
Cortex −1.00 0.204
SLC6A2 16 Cortex 1.85 0.405
Caudate 0.69 0.454
SLC6A3 5 Nucleus accumbens 1.59 0.116
Hypothalamus 0.65 0.192
Logistic regression analysis involved 820 total participants, which included 167
grade 2 or greater CNS event cases and 653 efavirenz-tolerant controls. The
analysis controlled for CYP2B6/CYP2A6 genotype level, age, sex, and the first 2
principal components. The analyses included all evaluable participants without
stratification for race/ancestry. The two lowest P-value results are shown for six
genes postulated to mediate efavirenz CNS side effects. The positive or negative
β indicates directionality of the relationship.
CNS, central nervous system.
and HTR6 in cortex (r2=0.029). These would not be con-
sidered well-predicted genes.
Predicted expression levels for all evaluable genes in
brain and CNS adverse events
In secondary analyses, we explored associations with
expression across all evaluable autosomal genes in the brain.
Among all participants, and controlling for CYP2B6/CYP2A6
genotype level, age, sex, and two principal components, the
lowest nominal P value was for RCE1 (a metalloproteinase) in
cerebellar hemisphere (P=5.3×10−8). The two lowest
nominal P-value results for each brain region are presented in
Table 3. In analyses performed separately among White,
Black, and Hispanic participants, and adjusted for age and sex
but not principal components, there were no significant
associations after adjusting for multiple comparisons. The
lowest P value inWhite participants was for ACSF3 in anterior
cingulate cortex (P=9.5×10−6), in Black participants was for
TRPC3 in cerebellar hemisphere (P=1.9×10−5), and in
Hispanics participants was for KLK5 in cerebellar hemisphere
(P=3.0×10−5). The two lowest nominal P-value genes for
each brain region each gene within race/ethnicity group are
presented in Supplementary Table 2 (Supplemental digital
content 1, http://links.lww.com/NMC/A133).
Predicted UGT1A1 expression in all tissues and baseline
plasma bilirubin concentration
As a positive control we considered total plasma bilirubin
concentration at baseline, which should correlate inversely
with UGT1A1 expression, especially in liver. By linear
regression analysis involving 1354 participants evaluable
for baseline plasma bilirubin, and controlling for CYP2B6/
CYP2A6 genotype, age, sex, and two principal components,
hepatic UGT1A1 expression was associated with bilirubin
concentration (P=3.4×10−27). This association was also
present among White participants (P=4.3×10−15), Black
participants (P=4.2×10−12), and Hispanic participants
(P=1.5×10−6) analyzed separately without adjusting for
principal components (Table 4). In contrast, for 17 nonliver
tissues for which PrediXcan could predict UGT1A1 expres-
sion levels, only three had nominal P values less than 0.05
for association of UGT1A1 expression with baseline total
bilirubin – skeletal muscle (P=0.002), non-sun-exposed skin
(P=0.005), and putamen (P=0.046). P values exceeded
0.10 for the other 14 tissues. This established that PrediXcan
could identify a true gene expression–phenotype association
in our dataset, and could do so in a tissue-specific manner.
Neurotransmitter transporter/receptor gene
polymorphisms and CNS adverse events
Primary analyses characterized associations between
polymorphisms in the eight neurotransmitter transporter/
receptor genes (± 100 kB) noted above (SLC6A2, SLC6A3,
NR3C3, HTR2A, HTR2B, HTR2C, HTR6, NR3C4) and
grade 2 or greater CNS adverse events within 48 weeks.
Analysis among all participants, and controlling for
CYP2B6/CYP2A6 genotype level, age, sex, and two
principal components, the lowest nominal P value was for
rs12393326 in HTR2C (P= 6.7× 10− 4). The two lowest
nominal P-value polymorphisms among all participants
and among White, Black, and Hispanic participants ana-
lyzed separately are presented in Table 5. None were
significant after correcting for multiple testing.
Genome-wide polymorphisms and CNS adverse events
To complement the above analyses focused on eight
neurotransmitter transporter/receptor gene polymorph-
isms, secondary analyses explored polymorphism asso-
ciations genome-wide. Analysis among all participants,
and controlling for CYP2B6/CYP2A6 genotype level, age,
Table 3 Associations between predicted expression levels of all
genes in brain and grade 2 or greater central nervous system
adverse events within 48 weeks of starting efavirenz-containing
regimens
Brain regions Gene Chromosome β P value
Anterior cingulate cortex PAXBP1 21 –6.73 1.7×10–6
SEMA3G 3 2.80 2.8×10–6
Caudate EMC10 19 2.79 1.0×10–5
SIRPB1 20 1.52 1.9×10–5
Cerebellar hemisphere RCE1 11 –2.64 5.3×10–8
RABEPK 9 –1.21 4.6×10–6
Cerebellum CDK10 16 –0.73 1.8×10–5
C4orf48 4 –4.90 4.9×10–5
Cortex TFAP2D 6 –6.61 1.2×10–6
EHMT1 9 –1.44 1.1×10–4
Frontal cortex ZNF76 6 –59.49 2.2×10–6
HLA-G 6 0.59 1.5×10–4
Hippocampus C11orf68 11 –2.45 5.3×10–8
ZNF555 19 42.89 7.6×10–6
Hypothalamus IKBKE 1 0.10 2.7×10–7
ADRBK1 11 4.63 2.4×10–6
Nucleus accumbens SHANK3 22 4.80 2.9×10–7
MSX2 5 –4.92 1.2×10–4
Putamen UBL4B 1 5.62 1.0×10–5
SMIM6 17 –1.49 1.0×10–5
Logistic regression analysis involved 820 total participants, which included 167 grade
2 or greater CNS event cases and 653 efavirenz-tolerant controls. The analysis
controlled for CYP2B6/CYP2A6 genotype level, age, sex, and the first 2 principal
components. The analyses included all evaluable participants without stratification for
race/ancestry. The two lowest P-value results are shown for each brain region.
CNS, central nervous system.
Table 4 Associations between baseline plasma total bilirubin
concentration and predicted gene expression levels in liver
Race/
ethnicity Gene Chromosome Participants β P value
All UGT1A1 14 1354 0.30 3.4×10–27
GGACT 2 1354 −0.88 7.2×10–6
White UGT1A1 2 645 0.32 4.9×10–15
CSN1S1 4 645 −0.37 8.7×10–5
Black UGT1A1 2 458 0.30 4.2×10–12
PGBD2 1 458 −1.96 3.6×10−5
Hispanic CLDN12 7 282 −4.17 3.7×10–7
UGT1A1 2 282 0.33 1.5×10–6
Linear regression analysis involved numbers of participants shown, for baseline
plasma total bilirubin concentration. Analysis among all participants controlled for
CYP2B6/CYP2A6 genotype level, age, and sex. Analysis among White, Black,
and Hispanic participants controlled for the same covariates but did not control
for principal components. The two lowest P-value results are shown for each
population group.
sex, and two principal components, the lowest nominal
P value was for rs7143465 in SLC8A3, which encodes
solute carrier family 8 member A3 (P= 2.2× 10− 9). The
two lowest nominal P-value polymorphisms among all
participants and among White, Black, and Hispanic par-
ticipants analyzed separately are presented in Table 6.
For the four genes in Table 6, we attempted to examine
whether predicted expression in brain was associated with
CNS events. Of these, CFAP36 was not represented in
PrediXcan. Among White participants, but not among Black
or Hispanic participants, predicted ACSF3 expression in brain
tissues tended to be associated with grade 2 or greater CNS
adverse events within 48 weeks, including in anterior cingu-
late cortex (P=9.46×10−6), frontal cortex (P=1.08×10−5),
cortex (1.24×10−5), and caudate (P=8.53×10−5). Of note,
ACSF3 rs144103499 (Table 6) is not a known expression
quantitative trait locus for ACSF3 in any tissue [42]. There
were not associations with BBS12 or SLC8A3. The lowest
P value for BBS12 was in cerebellum among Black partici-
pants (P=0.092), and for SLC8A3 was in hypothalamus
among all participants (P=0.014).
Discussion
Among individuals who were randomly assigned to initial
treatment with efavirenz-containing regimens in four
ACTG studies, and with correction for multiple com-
parisons, we found no significant association between
predicted expression of six neurotransmitter transporter
and receptor genes postulated to mediate efavirenz
effects in brain (SLC6A2, SLC6A3, PGR, HTR2A, HTR2B,
HTR6) and grade 2 or greater CNS adverse events, both
among all participants, and in analyses performed separately
among White, Black, and Hispanic participants. The lowest
nominal P value among all participants was for PGR in
hippocampus (P= 0.012). Similarly, after correction for
multiple comparisons we found no significant association
between individuals SNPs in these genes or AR and
HTR2C and grade 2 or greater CNS adverse events, both
among all participants, and in analyses performed sepa-
rately among White, Black, and Hispanic participants. The
lowest nominal P value was for rs12393326 in HTR2C
(P= 6.7× 10−4).
Analyses were controlled for CYP2B6/CYP2A6 genotype,
age, and sex, and, in analyses that pooled all race/ethni-
city groups, also the first two principal components. We
demonstrated significant, though weak, associations
between CYP2B6/CYP2A6 genotype level and grade 2 or
greater CNS adverse events, which is generally con-
sistent with several previous reports [18,23,24]. It was
therefore important that we adjust for CYP2B6/CYP2A6
genotype level in analyses for associations with predicted
neurotransmitter transporter/receptor gene expression
and polymorphisms. In addition, controlling for principal
components in analyses involving all participants reduced
Table 5 Associations between polymorphisms in eight neurotransmitter/transporter genes and grade 2 or greater central nervous system
adverse events within 48 weeks of starting efavirenz
Race/ethnicity Polymorphism Gene Chromosome MAF Cases Controls β SE P value
All rs12393326 HTR2C X G:0.07 164 815 0.53 0.16 6.7×10–4
rs5988149 HTR2C X A:0.12 165 816 0.38 0.13 3.6×10–3
White rs660541 PGR 11 A:0.51 83 281 0.41 0.18 2.2×10–2
rs511484 PGR 11 C:0.49 83 281 −0.36 0.16 2.3×10–2
Black rs2497509 HTR2C X C:0.43 49 211 0.59 0.18 8.8×10–4
rs2497510 HTR2C X A:0.43 49 211 0.59 0.18 8.8×10–4
Hispanic rs3785152 SLC6A2 16 T:0.08 26 158 1.09 0.46 1.8×10–2
rs2016711 HTR2A 13 G:0.03 26 158 1.34 0.61 2.8×10–2
Logistic regression analysis involved the indicated numbers of grade 2 or greater CNS event cases and efavirenz-tolerant controls. We considered polymorphisms in
SLC6A2, SLC6A3, NR3C3, HTR2A, HTR2B, HTR2C, HTR6, and NR3C4 ±100 kB. The analysis controlled for CYP2B6/CYP2A6 genotype level, age, sex, and, for the
analysis involving all participants, the first two principal components. The two lowest P-value results are shown for each race/ancestry group.
CNS, central nervous system; MAF, minor allele frequency.
Table 6 Associations between genome-wide polymorphisms and grade 2 or greater central nervous system adverse events within 48 weeks
of starting efavirenz
Race/ethnicity Polymorphism Gene Chromosome MAF Cases Controls β SE P value
All rs7143465 SLC8A3 14 C:0.45 167 653 −0.69 0.12 2.2×10–9
rs1045920 CFAP36 2 T:0.45 166 653 −0.74 0.13 2.6×10–9
Black rs2292493 BBS12 4 T:0.13 52 211 1.60 0.31 2.9×10–7
rs72671080 BBS12 4 A:0.13 52 211 1.60 0.31 3.0×10–7
Hispanic rs62520409 LOC105375706 8 A:0.04 26 158 3.34 0.68 9.8×10–7
rs1305010 Intergenic 2 C:0.06 26 157 2.31 0.54 1.9×10–5
White rs10823547 Intergenic 10 G:0.50 82 281 −0.88 0.18 1.2×10–6
rs144103499 ACSF3 16 CCT:0.21 83 280 1.04 0.22 1.3×10–6
Logistic regression analysis involved the indicated numbers of grade 2 or greater CNS event cases and efavirenz-tolerant controls. The analysis controlled for CYP2B6/
CYP2A6 genotype level, age, sex, and, for the analysis involving all participants, the first two principal components. The two lowest P-value results are shown for each race/
ancestry group.
CNS, central nervous system; MAF, minor allele frequency.
the likelihood for false associations due to unrecognized
population stratification.
PrediXcan is a relatively new computational algorithm
that allows the heritable component of RNA expression
levels for individual genes in different tissues to be
inferred from genome-wide genotype data [25]. It was
developed to exploit genotype-tissue expression data,
and evaluates aggregate effects of cis-regulatory variants
(within 1MB upstream or downstream) on gene expres-
sion by an elastic net regression method, and generates
potential expression quantitative trait loci and their
weights for each gene in each genotype-tissue expression
tissue type. By considering genes rather than individual
polymorphisms, PrediXcan should have a greatly reduced
multiple testing burden versus single-variant-single-trait
association tests. PrediXcan may therefore identify loci
with modest to weak effect sizes that are not significant
in genome-wide association studies. To assess the per-
formance of PrediXcan we tested for associations with
baseline plasma total bilirubin concentration. It is reas-
suring that we found significant associations between
predicted UGT1A1 expression in liver and bilirubin
concentrations among all participants, and separately
among White, Black, and Hispanic participants. Thus,
PrediXcan detected a known association in a tissue-
specific manner in our dataset.
By analyzing all participants pooled, as well as racial/
ethnic groups of White, Black, and Hispanic participants
separately, we had the potential to identify consistent
genetic associations across groups. Although true genetic
associations need not be present in all populations,
finding the same association in all participants and in
each race/ethnicity group increases the likelihood that
the association is not by chance. For example, associa-
tions between CYP2B6 genotype level and plasma efa-
virenz concentrations were previously shown in pooled
analyses and among White, Black, and Hispanic partici-
pants analyzed separately [15]. In the present analyses,
neither predicted gene expression levels or polymorph-
isms with the lowest P values were consistent across
populations.
We cannot explain the apparent association between
female sex and fewer grade 2 or greater CNS adverse
events among all participants, and among White partici-
pants and Black participants analyzed separately. Previous
reports have been inconsistent in this regard, with studies
showing no difference by sex [43,44], increased efavirenz
CNS adverse events in males [45], and increased CNS
adverse events in females [46].
This study has limitations. Because providers may not
have referred patients perceived to be at increased risk for
CNS adverse events to studies of efavirenz, risk may be
underestimated. Analyses largely involved White, Black,
and Hispanic participants in the USA, so findings may
not translate to other countries or race/ethnicity groups.
The open-label design of three of the four studies might
have biased investigators into reporting CNS adverse
events in patients randomized to efavirenz. Although
PrediXcan readily identified an association between pre-
dicted UGT1A1 expression in liver and bilirubin con-
centrations, this does not prove that we could detect
associations of efavirenz CNS adverse events with pre-
dicted gene expression levels in brain. To our knowledge,
there is no brain gene–phenotype pair in our dataset that
could serve as a positive control. A larger sample size
would increase power to identify associations. The pre-
sent study was not designed to address rare polymorph-
isms, epigenetics, inducibility of gene expression, and
trans-regulatory elements. In addition, factors not eval-
uated in this study such as nicotine and alcohol use may
affect expressions of CYP2B6, CYP2A6, and other genes,
and could conceivably differ by ancestry.
Conclusion
It is important to identify genetic factors that affect suscept-
ibility to antiretroviral toxicities. The present study suggests
that interindividual differences in brain neurotransmitter
transporter/receptor genomics may not explain variable sus-
ceptibility to efavirenz CNS adverse events.
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